Schering-Plough May Settle for Less on Clotting Partnership

Schering-Plough has been playing hard to get when it comes finding another company to help commercialize an experimental anti-clotting drug that looks like a jewel in the drugmaker’s pipeline. But Schering-Plough might settle for a less than ideal candidate as the company muddles through a slump in sales of cholesterol drug Vytorin sales and a [...]